CHTF18

Across TCGA pan-cancer cohorts, CHTF18 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHTF18 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHTF18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHTF18 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, OV, and LUAD are the cancer types where CHTF18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.377	0.637	.013	10	view →
OV	DFS	Median	All	0.870	1.000	.044	4	view →
LUAD	DFS	Tertile	II,III,IV	0.991	0.790	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHTF18–PDAC (DFS)

Open the PDAC breakdown →